Disc Medicine (NASDAQ:IRON – Get Free Report) had its price objective cut by Morgan Stanley from $75.00 to $40.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 26.78% from the stock’s previous close. A […]
Disc Medicine (NASDAQ:IRON – Get Free Report) had its price objective cut by Morgan Stanley from $75.00 to $40.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 26.78% from the stock’s previous close. A […]
Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light.
Disc Medicine (NASDAQ:IRON) Shares Gap Down to $62 26 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.